Endoscopy Unit, Humanitas Research Hospital
Rozzano, Milano, 20089, Italy
NCT Number: NCT04589078
Diminutive colorectal polyps (≤ 5 mm) represent most of the polyps detected during colonoscopy, especially in the rectum-sigmoid tract. The characterization of these polyps by virtual chromoendoscopy is recognized as a key element for innovative imaging techniques. As a matter of facts diminutive colorectal polyps are very frequent and, if located in the rectosigmoid colon, they present a very low malignant risk (0.3% of evolution towards advanced adenoma and up to 0.08% of evolution towards invasive carcinoma). The real-time characterization would allow to identify the lowest risk polyps (hyperplastic subtype), to leave them in situ or, if resected, not to send them for histological examination, allowing a huge saving in healthcare associated costs.
Recently, the American Society for Gastrointestinal Endoscopy (ASGE) Technology Committee established the Preservation and Incorporation of Valuable endoscopic Innovations (PIVI) document, specific for real-time histological assessment for tiny colorectal polyps, to establish reference quality thresholds. Two performance standards have been developed to guide the use of advanced imaging:
1. for diminutive polyps to be resected and discarded without pathologic assessment, endoscopic technology (when used with high confidence) used to determine histology of polyps ≤ 5mm in size, when combined with the histopathology assessment of polyps > 5 mm in size, should provide a ≥ 90% agreement in assignment of post-polypectomy surveillance intervals when compared to decisions based on pathology assessment of all identified polyps; 2. in order for a technology to be used to guide the decision to leave suspected rectosigmoid hyperplastic polyps ≤ 5 mm in size in place (without resection), the technology should provide ≥ 90% negative predictive value (when used with high confidence) for adenomatous histology.
Computer-Aided-Diagnosis (CAD) is an artificial intelligence-based tool that would allow rapid and objective characterization of these lesions. The GI Genius CADx was developed to help endoscopists in their clinical practices for polyps characterization.
Looking for future studies?
Notify Me40 year–80 year
All sexes
Observational
Rozzano, Milano, 20089, Italy
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
Time frame: 1 day
Time frame: 1 day
Agreement in assignment of post-polypectomy surveillance intervals according to established guidelines between:
Time frame: 1 day
Cosmo Artificial Intelligence-AI Ltd
Industry
Acronym: PREDICT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07722208
Artificial Intelligence
Cairo, Egypt
View Trial DetailsNCT07376434
Artificial Intelligence, Behavior
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07547293
Artificial Intelligence, Attitude
Istanbul, Kavacık, Turkey (Türkiye)
View Trial DetailsNCT07387718
Artificial Intelligence, Asthma in Children
Miami, Florida, United States
View Trial Details